Melanoma vaccine - AVAX Technologies

Drug Profile

Melanoma vaccine - AVAX Technologies

Alternative Names: DNP-VACC; M-Vax; Melanoma vaccine DNP VACC; MVax

Latest Information Update: 21 Oct 2015

Price : $50

At a glance

  • Originator AVAX Technologies
  • Class Cancer vaccines; Dinitrobenzenes; Haptens
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Malignant melanoma

Most Recent Events

  • 04 Aug 2015 Phase III development is ongoing in USA
  • 01 Dec 2011 Phase-III clinical trials in Malignant melanoma in USA (Intradermal)
  • 01 Dec 2011 Phase-III clinical trials in Malignant melanoma in Belgium (Intradermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top